12:00 AM
Oct 08, 2012
 |  BC Week In Review  |  Company News  |  Other News

Amgen, Galaxy, GlaxoSmithKline cancer news

Galaxy said the European Patent Office's Opposition Board upheld Galaxy's patent covering a humanized mAb against hepatocyte growth factor/scatter factor (HGF/SF) following opposition from Amgen and GlaxoSmithKline. The patent - European Patent Number EP 1 734 995 B1 - expires in 2024. According to Galaxy, Amgen and GSK filed statements of opposition in...

Read the full 252 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >